

PRODUCT INFORMATION




Nicardipine (hydrochloride)

Item No. 17537

CAS Registry No.: 54527-84-3
Formal Name: 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid, 3-methyl 5-[2-[methyl(phenylmethyl)amino]ethyl] ester, monohydrochloride

Synonym: RS 69216
MF: C₂₆H₂₉N₃O₆ • HCl
FW: 516.0
Purity: ≥98%
UV/Vis.: λ_{max}: 236, 352 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nicardipine (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the nicardipine (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Nicardipine (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of nicardipine (hydrochloride) in ethanol is approximately 1 mg/ml and approximately 20 mg/ml in DMSO and DMF.

Nicardipine (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, nicardipine (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Nicardipine (hydrochloride) has a solubility of approximately 0.25 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Nicardipine is a dihydropyridine L-type calcium channel antagonist that displays antihypertensive and antianginal activity.¹ It is reported to inhibit adenosine A₁, A_{2A}, and A₃ receptors with K_i values of 19.6, 63.8, and 3.25 μM, respectively, and can inhibit cytochrome P450 3A4 catalytic activity with an IC₅₀ value of 0.148 μM.^{2,3} Additionally, nicardipine has been shown to activate transient receptor potential A1 channels, producing an increase in Ca²⁺ (EC₅₀ = 0.5 μM).⁴

References

1. Triggle, D.J. and Rampe, D. 1,4-Dihydropyridine activators and antagonists: Structural and functional distinctions. *Trends Pharmacol. Sci.* **10(12)**, 507-511 (1989).
2. van Rhee, A.M., Jiang, J.L., Melman, N., *et al.* Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: Selectivity for A₃ receptors. *J. Med. Chem.* **39(15)**, 2980-2989 (1996).
3. Stresser, D.M., Blanchard, A.P., Turner, S.D., *et al.* Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. *Drug Metab. Dispos.* **28(12)**, 1440-1448 (2000).
4. Baraldi, P.G., Preti, D., Materazzi, S., *et al.* Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. *J. Med. Chem.* **53(14)**, 5085-5107 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM